GlassScriptPhysician profile
Awol Y Ali
NPI 1720165277
$6,830.44
in general payments reported to CMS, 2019-2025
22 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $403 · 2021: $937 · 2022: $962 · 2023: $1,027 · 2024: $987 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.08 |
| Education | $183.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,384.84 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $1,039.47 | 2019-2025 | Yeztugo, Biktarvy, Veklury |
| Janssen Biotech, INC. | $628.37 | 2019-2023 | Symtuza |
| Abbvie INC. | $621.61 | 2021-2025 | Dalvance, Avycaz |
| Merck Sharp & Dohme LLC | $613.08 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $588.22 | 2021-2025 | Fetroja |
| Melinta Therapeutics, LLC | $366.10 | 2019-2025 | Rezzayo, Vabomere, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $362.49 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $337.60 | 2019-2023 | Trogarzo, Egrifta |
| Insmed, INC. | $286.79 | 2019-2025 | Arikayce, Brinsupri |
| Vyera Pharmaceuticals, LLC | $108.76 | 2019-2022 | |
| Janssen Products, LP | $99.00 | 2019 | |
| Napo Pharmaceuticals INC | $62.67 | 2019-2022 | |
| Allergan, INC. | $58.63 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $43.73 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $43.69 | 2022-2023 | Rebyota |
| Astellas Pharma US INC | $43.30 | 2019-2023 | Cresemba |
| Nabriva Therapeutics, Plc | $39.54 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $36.59 | 2022-2023 | Xerava |
| Aimmune Therapeutics, INC. | $31.20 | 2024 | |
| Dynavax Technologies Corporation | $17.58 | 2022 | |
| Pharming Healthcare, INC. | $17.18 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Awol Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.